B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00

Craig Hallum initiated coverage of biote Corp. with a rating of Buy

B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

Jefferies initiated coverage of biote Corp. with a rating of Buy

8-K - biote Corp. (0001819253) (Filer)

8-K - biote Corp. (0001819253) (Filer)

SCHEDULE 13G/A - biote Corp. (0001819253) (Subject)

10-Q - biote Corp. (0001819253) (Filer)

8-K - biote Corp. (0001819253) (Filer)

S-8 - biote Corp. (0001819253) (Filer)

8-K - biote Corp. (0001819253) (Filer)

DEFA14A - biote Corp. (0001819253) (Filer)

DEF 14A - biote Corp. (0001819253) (Filer)

10-K - biote Corp. (0001819253) (Filer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4/A - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

3 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro

Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting

Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be avai

Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of the

Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per share attributable to biote Corp. stockholders of $0.22, compared to net income of $12.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.33 in the prior year period Adjusted EBITDA1 of $12.9 million and Adjusted EBITDA margin1 of 26.9% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the heal

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast w

Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro

Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting

Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

Ms. Puncochar to Drive Execution of Biote's Strategic Sales and Marketing Initiatives biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote's commercial initiatives to expand the Company's presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biot

Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be avai

Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of the

Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per share attributable to biote Corp. stockholders of $0.22, compared to net income of $12.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.33 in the prior year period Adjusted EBITDA1 of $12.9 million and Adjusted EBITDA margin1 of 26.9% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the heal

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast w

Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13G/A - biote Corp. (0001819253) (Subject)

SC 13D - biote Corp. (0001819253) (Subject)

SC 13G - biote Corp. (0001819253) (Subject)

SC 13G - biote Corp. (0001819253) (Subject)